Taletrectinib Cost-Effectiveness Analysis for ROS1+ NSCLC in the United States

A partitioned survival model analysis from 2026 evaluates the cost-effectiveness of four treatment strategies for ROS1-positive non-small cell lung cancer. The study, authored by Gengwei Huo and shared on figshare, compares first-line and second-line taletrectinib use against chemotherapy alone, calculating incremental cost-effectiveness ratios (ICERs) against a $150,000 per QALY willingness-to-pay threshold. Results indicate none of the taletrectinib-containing strategies were cost-effective at current pricing.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) for different NSCLC treatment sequences based on the model results.
• Analyze the impact of drug pricing on cost-effectiveness outcomes based on the sensitivity analysis described.
• Evaluate quality-adjusted life year (QALY) gains from different treatment strategies based on the reported QALY values.
• Model healthcare expenditures for ROS1-positive NSCLC treatments based on the cost data from literature and public databases.

Strengths

• Specific QALY gains are reported, such as 4.61372 QALYs for first-line taletrectinib.
• Exact incremental costs are provided, such as $1,263,183.95 for the first-line strategy.
• Clear ICERs are calculated, including $273,789 per QALY for first-line taletrectinib vs. chemotherapy.
• Analysis uses a defined U.S. willingness-to-pay threshold of $150,000 per QALY.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a single 84.5 KB PDF file, indicating a limited scope of contained data.

Provenance

Source

Gengwei Huo via figshare.

Collection Method

A partitioned survival model constructed using costs and utility values from literature and public cost databases.

Time Range

Analysis published in 2026.

Freshness

Last updated 2026-04-13 04:35:09; freshness should be verified.

Geography

United States.